Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-02 18:49:05 - browse：68

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： See how much Covid

WSS

How to increase colonoscopy rates? Looks like an AI can help

NIH confirmation hearing shows politicization of research

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Ultragenyx gene therapy for rare liver ailment succeeds in late

STAT Readout Newsletter: Today's biggest biotech updates

Change Healthcare can notify patients about the breach, HHS says

hotspot

Wikipedia

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Summit: GSK CEO on pharma giant's new direction

United colonoscopy coverage change 'may cost lives,' doctors say

The Pandemic Treaty must support building strong health systems

Medical leaders decry Supreme Court decision on affirmative action

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Guidelines to prevent youth baseball injuries need more muscle

Medicare reduced heart disease by changing how it pays doctors

Walensky prepares to leave CDC — and Congress — behind

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

knowledge

Pharmacists can make shortage drugs, but at what cost?

With trial win, GSK could get blood cancer drug back on market

NIH documents show early flaws of $1.6 billion long Covid program

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

NIH documents show early flaws of $1.6 billion long Covid program

Will Ozempic

focus

focus

leisure time

Wikipedia